The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer

被引：7
|
作者：
Santana-Davila, Rafael [1 ]
Chow, Laura Q. M. [1 ]
机构：
[1] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA 98195 USA
来源：
FUTURE ONCOLOGY | 2018年 / 14卷 / 03期
关键词：
chemo-immunotherapy; first-line; immune checkpoint inhibitors; immunotherapy; lung cancer; NSCLC; treatment naive; PACLITAXEL PLUS CARBOPLATIN; OPEN-LABEL; PHASE-III; PEMBROLIZUMAB; NIVOLUMAB; DOCETAXEL; CHEMOTHERAPY; MULTICENTER; IPILIMUMAB;
D O I：
10.2217/fon-2017-0124
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：191 / 194
页数：4
相关论文
共 50 条
  • [1] Emerging Immunotherapies for Advanced Non-Small-Cell Lung Cancer
    Wolf, Emily
    Sacchi de Camargo Correia, Guilherme
    Li, Shenduo
    Zhao, Yujie
    Manochakian, Rami
    Lou, Yanyan
    VACCINES, 2025, 13 (02)
  • [2] Immunotherapy alone or chemo-immunotherapy as front-line treatment for advanced non-small cell lung cancer
    Shafique, Michael
    Tanvetyanon, Tawee
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (03) : 225 - 232
  • [3] Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer
    Reck, Martin
    IMMUNOTHERAPY, 2018, 10 (02) : 93 - 105
  • [4] The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice
    Zouein, Joseph
    Haddad, Fady G.
    Eid, Roland
    Kourie, Hampig R.
    IMMUNOTHERAPY, 2022, 14 (02) : 155 - 167
  • [5] Supportive care in the era of immunotherapies for advanced non-small-cell lung cancer
    Awada, Gil
    Klastersky, Jean
    CURRENT OPINION IN ONCOLOGY, 2018, 30 (02) : 98 - 104
  • [6] Durvalumab in non-small-cell lung cancer patients: current developments
    Mezquita, Laura
    Planchard, David
    FUTURE ONCOLOGY, 2018, 14 (03) : 205 - 222
  • [7] Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer
    Reckamp, Karen L.
    Lin, Huamao M.
    Cranmer, Holly
    Wu, Yanyu
    Zhang, Pingkuan
    Walton, Laura J.
    Kay, Stephen
    Cichewicz, Allie
    Neupane, Binod
    Fahrbach, Kyle
    Popat, Sanjay
    Camidge, D. Ross
    FUTURE ONCOLOGY, 2022, 18 (20) : 2499 - 2510
  • [8] Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer
    Yang, Szu-Chun
    Ou, Huang-Tz
    Su, Wu-Chou
    Wang, Shi-Yi
    CANCER MEDICINE, 2023, 12 (07): : 8838 - 8850
  • [9] Nivolumab plus ipilimumab in non-small-cell lung cancer
    Reck, Martin
    Borghaei, Hossein
    O'Byrne, Kenneth J.
    FUTURE ONCOLOGY, 2019, 15 (19) : 2287 - 2302
  • [10] First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light
    Ackermann, Christoph Jakob
    Reck, Martin
    Paz-Ares, Luis
    Barlesi, Fabrice
    Califano, Raffaele
    LUNG CANCER, 2019, 134 : 245 - 253
12345